Arkansas Administrative Code › Agency 006 - Department of Finance and Administration › Division 06 - Racing Commission › Rule 006.06.20-005 - Thoroughbred Rule 1217E Furosemide

Current through Register Vol. 49, No. 6, June, 2024
E.
Furosemide as a permitted foreign
			 substance
Except as otherwise provided in Rule 1232(5):
Furosemide may be administered intravenously to a horse, which
				is entered to compete in a race. Except under the instructions of the
				commission veterinarian or the racing veterinarian for the purpose of removing
				a horse from the veterinarian's list or to facilitate the collection of a
				post-race urine sample, furosemide shall be permitted only after the commission
				veterinarian has placed the horse on the furosemide list. In order for a horse
				to be placed on the furosemide list, the following process must be
				followed:
(1) After the horse's
			 licensed trainer and practicing veterinarian determine that it would be in the
			 horse's best interests to race with furosemide, they shall notify the official
			 veterinarian or his/her designee, using the prescribed form, that they wish the
			 horse to be put on the furosemide list.
(2) The form must be received by the
			 commission veterinarian or his/her designee by the proper time deadlines so as
			 to ensure public notification.
(3)
			 A horse placed on the official furosemide list must remain on that list unless
			 the licensed trainer and practicing veterinarian submit a written request to
			 remove the horse from the list. The request must be made to the commission
			 veterinarian or his/her designee, on the proper form, no later than the time of
			 entry.
(4) After a horse has been
			 removed from the furosemide list, the horse may not be placed back on the list
			 for a period of sixty (60) calendar days unless it is determined to be
			 detrimental to the welfare of the horse, in consultation with the commission
			 veterinarian. If a horse is removed from the official furosemide list a second
			 time in a three hundred sixty-five (365) day period, the horse may not be
			 placed back on the list for a period of ninety (90) calendar days.
(5) Furosemide shall only be administered on
			 association grounds.
(6) Upon the
			 request of the regulatory agency designee, the veterinarian administering the
			 authorized bleeder medication shall surrender the syringe used to administer
			 such medication, which may then be submitted for testing.
(7) Time of treatment. Horses qualified for
			 medication and so indicated on the official bleeder list must be treated at
			 least four (4) hours prior to post time.
(8) Medication administration. Bleeder
			 medication shall be administered by a veterinarian licensed by the commission
			 at an intravenous dose level not to exceed two hundred fifty (250) milligrams
			 and no less than one hundred fifty (150) milligrams; provided, with approval of
			 the official veterinarian, a dose of up to five hundred (500) milligrams may be
			 administered. Administration of furosemide shall take place in the horse's
			 stall or a specific location otherwise designated by the commission
(9) Out-of-state horses. A bleeder horse
			 shipped into the state from another jurisdiction may be automatically eligible
			 to receive furosemide provided that the jurisdiction from which it was shipped
			 qualified it as a bleeder using criteria satisfactory to this state. The Daily
			 Racing Form, Equibase, the breed registry foal certificate, or bleeder
			 certificate may be utilized in determining a horse's eligibility to receive
			 furosemide.
(10) The test level of
			 furosemide under this rule shall not be in excess of fifty (50) nanograms per
			 milliliter of serum or plasma and shall not be below a urine specific gravity
			 of one and ten one-thousandths (1.010); provided, if the official veterinarian
			 shall have approved a dose of up to 500 milligrams of furosemide, the test
			 level of furosemide under this rule shall not be in excess of one hundred (100)
			 nanograms per milliliter of serum or plasma and shall not be below a urine
			 specific gravity of one and ten one-thousandths (1.010). If an insufficient
			 volume of urine is obtained, a positive test shall be based upon quantitative
			 testing performed on blood serum or plasma only. Split sample testing shall be
			 quantitative and be performed on blood serum or plasma only.